Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Can yervoy cause any serious complications?

See the DrugPatentWatch profile for yervoy

Yervoy (Ipilimumab) is a medication used to treat certain types of cancer, including melanoma and kidney cancer. While it can be an effective treatment, like all medications, it can also cause serious complications.

According to the FDA warning label [1], Yervoy can cause severe immune-mediated adverse reactions (IMRs), which can affect various parts of the body, including the skin, liver, kidney, thyroid, lung, and other organs.

Some potential serious complications of Yervoy treatment include:

* Immune-mediated colitis: Inflammation of the colon, which can cause diarrhea, abdominal pain, and fatigue [2].
* Immune-mediated hepatitis: Inflammation of the liver, which can cause fatigue, jaundice, and abdominal pain [3].
* Hypophysitis: Inflammation of the pituitary gland, which can affect hormone production and lead to symptoms such as headache, nausea, and fatigue.
* Dermatitis: Skin inflammation, which can cause rash, itching, and swelling.
* Pneumonitis: Inflammation of the lungs, which can cause cough, shortness of breath, and fatigue [4].

It's essential to note that these complications can be managed with proper monitoring and medical attention. Patients undergoing Yervoy treatment should closely follow their healthcare providers' instructions and report any symptoms or concerns promptly.

Sources:

[1] https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d9b0ad-5f3d-44a4-9a7e-4e6b5b1eb7b5 (Medication Guide for Yervoy)

[2] https://www.fda.gov/drugs/information-drug-class/potential-pyogenic-enterocolitis-risk-fda-drug-risk-evaluations (FDA warning: Potential pyogenic enterocolitis risk)

[3] https://www.rxlist.com/yervoy-medication-side-effects-drug-center.htm (Yervoy: Side effects, dosage, and pregnancy information)

[4] https://oncology.nutritionguide.org/2019/08/12/immunotherapy-associated-adverse-events/ (Immunotherapy-associated adverse events: A review of Yervoy's safety profile)

Sources:

1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d9b0ad-5f3d-44a4-9a7e-4e6b5b1eb7b5
2. https://www.fda.gov/drugs/information-drug-class/potential-pyogenic-enterocolitis-risk-fda-drug-risk-evaluations
3. https://www.rxlist.com/yervoy-medication-side-effects-drug-center.htm
4. https://oncology.nutritionguide.org/2019/08/12/immunotherapy-associated-adverse-events/



Other Questions About Yervoy :

How does yervoy's cost compare to other similar treatments? Are there any chemo drugs used with yervoy? When was yervoy first approved? How much can yervoy discount save per dose? When does yervoy's discount expire? How much of a discount does yervoy offer? In what cancer types is yervoy most effective?

AI-Drug Label Prescribing Information Alignment Report

64
64%
Grade C

Partial

Partially Aligned

Patient Risk: Moderate

Summary

Most organ-system immune-mediated adverse reaction assertions are supported by the provided label excerpt (5.1). However, multiple symptom and definition-style claims (e.g., diarrhea/abdominal pain/fatigue for colitis; jaundice/fatigue/abdominal pain for hepatitis; nausea for hypophysitis; itching/swelling/rash for dermatitis; cough/SOB/fatigue for pneumonitis; explicit “inflammation of X” definitions) are not supported in the provided label text, creating material gaps in accuracy.


Category Scores

Indication
55
Partial
Warnings
80
Good
AdverseReactions
60
Partial

Accurate Statements

Yervoy (ipilimumab) can cause severe immune-mediated adverse reactions (IMRs).
5.1: “Immune-mediated adverse reactions, which may be severe or fatal, can occur…”
Yervoy can cause immune-mediated adverse reactions that can affect the skin.
5.1: “Immune-Mediated Dermatologic Adverse Reactions… YERVOY can cause immune-mediated rash or dermatitis…”
Yervoy can cause immune-mediated adverse reactions that can affect the liver.
5.1: “Immune-Mediated Hepatitis… Immune-mediated hepatitis occurred…”
Yervoy can cause immune-mediated adverse reactions that can affect the kidneys.
5.1: “Immune-Mediated Nephritis with Renal Dysfunction… occurred…”
Yervoy can cause immune-mediated adverse reactions that can affect the thyroid.
5.1: Immune-Mediated Endocrinopathies including hypothyroidism, thyroiditis, hyperthyroidism.
Yervoy can cause immune-mediated adverse reactions that can affect the lungs.
5.1: “Immune-Mediated Pneumonitis… Immune-mediated pneumonitis occurred…”
Yervoy can cause immune-mediated colitis.
5.1: “Immune-Mediated Colitis… YERVOY can cause immune-mediated colitis, which may be fatal.”
Yervoy can cause immune-mediated hepatitis.
5.1: “Immune-Mediated Hepatitis… Immune-mediated hepatitis occurred…”
Yervoy can cause hypophysitis.
5.1: “YERVOY can cause immune-mediated hypophysitis… Hypophysitis occurred…”
Hypophysitis can affect hormone production.
5.1: “Hypophysitis can cause hypopituitarism. Initiate hormone replacement as clinically indicated.”
Hypophysitis can cause headache.
5.1: “Hypophysitis can present with… such as headache…”
Yervoy can cause dermatitis.
5.1: “YERVOY can cause immune-mediated rash or dermatitis…”
Yervoy can cause pneumonitis.
5.1: “Immune-Mediated Pneumonitis… Immune-mediated pneumonitis occurred…”

Unsupported Statements

Yervoy (ipilimumab) is a medication used to treat certain types of cancer, including melanoma and kidney cancer.
The provided excerpt does not include the formal indication statement from 1 INDICATIONS AND USAGE. The excerpt mentions RCC (kidney cancer) and melanoma within 5.1, but the overall treatment/indication wording is not provided.
Immune-mediated colitis is inflammation of the colon.
The provided label excerpt does not define colitis as “inflammation of the colon.”
Immune-mediated colitis can cause diarrhea.
No symptom of diarrhea is mentioned in the provided colitis excerpt.
Immune-mediated colitis can cause abdominal pain.
No symptom of abdominal pain is mentioned in the provided colitis excerpt.
Immune-mediated colitis can cause fatigue.
No symptom of fatigue is mentioned in the provided colitis excerpt.
Immune-mediated hepatitis is inflammation of the liver.
The provided excerpt does not explicitly define hepatitis as “inflammation of the liver.”
Immune-mediated hepatitis can cause fatigue.
No symptom of fatigue is mentioned in the provided hepatitis excerpt.
Immune-mediated hepatitis can cause jaundice.
No symptom of jaundice is mentioned in the provided hepatitis excerpt.
Immune-mediated hepatitis can cause abdominal pain.
No symptom of abdominal pain is mentioned in the provided hepatitis excerpt.
Hypophysitis can cause nausea.
Nausea is not mentioned in the provided hypophysitis excerpt.
Dermatitis is skin inflammation.
The provided excerpt mentions dermatitis but does not define it as “skin inflammation.”
Dermatitis can cause rash.
The excerpt lists “rash or dermatitis” as immune-mediated reactions, but does not state that dermatitis causes rash.
Dermatitis can cause itching.
Itching is not mentioned in the provided dermatologic excerpt.
Dermatitis can cause swelling.
Swelling is not mentioned in the provided dermatologic excerpt.
Pneumonitis is inflammation of the lungs.
The provided excerpt does not explicitly define pneumonitis as “inflammation of the lungs.”
Pneumonitis can cause cough.
Cough is not mentioned in the provided pneumonitis excerpt.
Pneumonitis can cause shortness of breath.
Shortness of breath is not mentioned in the provided pneumonitis excerpt.
Pneumonitis can cause fatigue.
Fatigue is not mentioned in the provided pneumonitis excerpt.

Contradictions


Important Omissions

Specific monitoring recommendations were not mentioned (e.g., baseline and before each dose evaluation of liver enzymes, creatinine, ACTH, and thyroid function; consider prompt medical management).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
While major immune-mediated adverse reaction categories align with the label excerpt, multiple symptom-level claims are unsupported in the provided text; additionally, key monitoring/management guidance present in 5.1 was omitted, which could reduce labeling accuracy for safe use.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Partially Aligned

Primary Issue
Numerous symptom/definition assertions are not supported by the provided label excerpt (5.1). Indication wording is only partially supported because the formal indications section text is not included in the excerpt.

Suggested Improvement
Remove or revise unsupported symptom and definition claims (e.g., diarrhea/abdominal pain/fatigue for colitis; jaundice/fatigue/abdominal pain for hepatitis; nausea for hypophysitis; itching/swelling/rash causality for dermatitis; cough/SOB/fatigue for pneumonitis). Limit adverse reaction descriptions to those explicitly stated in the excerpt, and incorporate the label’s monitoring recommendations (baseline and before each dose labs/ACTH/thyroid, prompt evaluation/management).

Drug Brand Mention Assessment

Branding Score
21
Visibility
37
Mentioned
Ranking
#1
Sentiment
10
Recommendation Status
discouraged
Brand Perception
Best Known For

used to treat certain types of cancer, including melanoma and kidney cancer


Core Claims
  • Yervoy (Ipilimumab) is used to treat certain types of cancer, including melanoma and kidney cancer.
  • Yervoy can cause severe immune-mediated adverse reactions (IMRs).
  • Severe complications can affect the skin, liver, kidney, thyroid, lung, and other organs.
  • Potential serious complications include immune-mediated colitis, immune-mediated hepatitis, hypophysitis, dermatitis, and pneumonitis.
Differentiators
  • Highlights severe immune-mediated adverse reactions (IMRs).
  • Lists complications affecting multiple organs (skin, liver, kidney, thyroid, lungs, and others).

Pricing Perception: Not Mentioned